Epidemiologic appraisal of hypertension as a coronary risk factor in the elderly

American Journal of Geriatric Cardiology

Volumn 11, Issue 2, 2002, Pages 86-92

  O'Donnell, Christopher J ^a   Kannel, William B ^a  

^a FRAMINGHAM HEART STUDY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; FIBRINOGEN; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ATHEROSCLEROSIS; COMORBIDITY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DYSLIPIDEMIA; FEMALE; GLUCOSE INTOLERANCE; HEART LEFT VENTRICLE HYPERTROPHY; HEART RATE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; MALE; OBESITY; PULSE PRESSURE; REVIEW; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; VASCULAR DISEASE;

EID: 0036276465     PISSN: 10767460     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1076-7460.2002.00996.x     Document Type: Review

References (34)

1. The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure
2. Hypertension as a cardiovascular risk factor
3. Blood pressure, stroke, and coronary heart disease. 2. Short-term reductions in blood pressure. Overview of randomized drug trials in their epidemiological context
4. Controlled clinical trials of drug treatment for hypertension. A review
5. Prevention of stroke in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP)
6. Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension
7. Systolic and diastolic pressures as predictors of coronary heart disease mortality in the Whitehall Study
8. Logistic model estimation of death attributable to risk factors for cardiovascular disease in Evans County, Georgia
9. Differential impact of systolic and diastolic blood pressure level on JNC VI staging
10. Systolic hypertension: A pathogenetic entity
11. High blood pressure, other risk factors, and longevity: The insurance viewpoint
12. A historical perspective of elevated systolic vs. diastolic blood pressure from an epidemiological and clinical trial viewpoint
13. Is the pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study
14. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction
15. Systolic versus diastolic blood pressure and the risk of coronary heart disease
16. Potency of vascular risk factors as the basis for antihypertensive therapy
17. Epidemiology of risk factor clustering in elevated blood pressure
18. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance
19. Insulin resistance, its consequences, and coronary heart disease. Must we choose one culprit?
20. Prediction of coronary heart disease using risk factor categories
21. Unrecognized myocardial infarction and hypertension
22. The prognostic significance of proteinuria: The Framingham Study
23. Influence of heart rate on mortality among persons with hypertension. The Framingham Study
24. Use of vital capacity for cardiac failure risk estimation in persons with coronary disease or left ventricular hypertrophy
25. Population implications of electrocardiographic left ventricular hypertrophy
26. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Study
27. Carotidartery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults
28. Angiotensin-converting enzyme inhibitors and the cardiovascular system
29. Relation of low diastolic blood pressure to coronary heart disease death in the presence of myocardial infarction: The Framingham Study
30. Risks of treated and untreated isolated systolic hypertension in the elderly: Meta-analysis of outcome trials
31. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension. Principal results of the Hypertension Optimal Treatment (HOT) randomized trial
32. Is there a preferred antihypertensive therapy for isolated systolic hypertension and reduced arterial compliance?
33. Cost-minimization and the number needed to treat in uncomplicated hypertension
34. Benefit of favorable cardiovascular risk factor profile in middle age with respect to Medicare costs